EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing of Doramectin as a New Anti-Zika Virus Agent

Yujia Zhu iD, Minqi Liang, Jianchen Yu, Bingzhi Zhang, Ge Zhu, Yun Huang, Zhenjian He, Jie Yuan

Viruses · 27.04.2023 · 15 (5) · 1068

DOI: 10.3390/v15051068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 27.04.2023. Verfasst von Yujia Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Sun Yat-sen University, Guangzhou 510080, China. Hauptthemen laut MEDLINE: Zika Virus, Zika Virus Infection. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Marine Economy Development Special Project, Natural Science Foundation of Guangdong Province, China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zika virus (ZIKV), belonging to the Flavivirus family and mainly transmitted by mosquitoes, causes a variety of adverse outcomes, including Guillain-Barré syndrome, microcephaly, and meningoencephalitis. However, there are no approved vaccines or drugs available for ZIKV. The discovery and research on drugs for ZIKV are still essential. In this study, we identified doramectin, an approved veterinary antiparasitic drug, as a novel anti-ZIKV agent (EC50 value from 0.85 μM to 3.00 μM) with low cytotoxicity (CC50 > 50 μM) in multiple cellular models. The expression of ZIKV proteins also decreased significantly under the treatment of doramectin. Further study showed that doramectin directly interacted with the key enzyme for ZIKV genome replication, RNA-dependent RNA polymerase (RdRp), with a stronger affinity (Kd = 16.9 μM), which may be related to the effect on ZIKV replication. These results suggested that doramectin might serve as a promising drug candidate for anti-ZIKV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zika VirusZika Virus InfectionAnimalsDrug RepositioningVirus ReplicationAntiviral AgentsIvermectin

Stichwörter der Autor:innen

RdRpZIKVantiviral agentdoramectin

Substanzen

Antiviral AgentsdoramectinIvermectin

Autor:innen und Institutionen

  • School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.
  • Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou 510080, China.
  • School of Chemistry, South China Normal University, Guangzhou 510006, China.
  • Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
  • School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
  • School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.

ORCID-Profile: Yujia Zhu

Förderung

  • Guangdong Marine Economy Development Special Project
  • Natural Science Foundation of Guangdong Province, China
  • National Natural Science Foundation of China

Zitieren

APA

Zhu, Y., Liang, M., Yu, J., Zhang, B., Zhu, G., Huang, Y., He, Z., & Yuan, J. (2023). Repurposing of Doramectin as a New Anti-Zika Virus Agent. Viruses, 15(5), 1068. https://doi.org/10.3390/v15051068

Vancouver

Zhu Y, Liang M, Yu J, Zhang B, Zhu G, Huang Y, et al. Repurposing of Doramectin as a New Anti-Zika Virus Agent. Viruses. 2023;15(5):1068. doi:10.3390/v15051068

BibTeX
@article{Zhu2023,
  author = {Zhu, Yujia and Liang, Minqi and Yu, Jianchen and Zhang, Bingzhi and Zhu, Ge and Huang, Yun and He, Zhenjian and Yuan, Jie},
  title = {Repurposing of Doramectin as a New Anti-Zika Virus Agent},
  journal = {Viruses},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1068},
  doi = {10.3390/v15051068}
}
Kostenlos starten →